COMPARISON OF THE CARDIOTOXICITY OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING REAL-WORLD DATA

被引：0
|
作者：
Hu, Jason
Aprikian, Armen
Vanhuyse, Marie
Dragomir, Alice
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP24-18
引用
收藏
页码：E418 / E419
页数：2
相关论文
共 50 条
  • [31] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [32] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [33] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [34] OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Cardoso, P.
    Santos, C.
    Costa, F.
    Goncalves, F. R.
    VALUE IN HEALTH, 2019, 22 : S445 - S445
  • [35] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [36] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
    Akira Yokomizo
    Junji Yonese
    Shin Egawa
    Hiroshi Fukuhara
    Hiroji Uemura
    Kazuo Nishimura
    Masayoshi Nagata
    Atsushi Saito
    Takumi Lee
    Susumu Yamaguchi
    Norio Nonomura
    International Journal of Clinical Oncology, 2022, 27 : 418 - 426
  • [38] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer
    M. van Nuland
    S. L. Groenland
    A. M. Bergman
    N. Steeghs
    H. Rosing
    N. Venekamp
    A. D. R. Huitema
    J. H. Beijnen
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 244 - 251
  • [40] Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
    Yokomizo, Akira
    Yonese, Junji
    Egawa, Shin
    Fukuhara, Hiroshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Nagata, Masayoshi
    Saito, Atsushi
    Lee, Takumi
    Yamaguchi, Susumu
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 418 - 426
12345